Immix Biopharma, Inc. (IMMX) 10-Year Financial Performance & Capital Metrics

IMMX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutImmix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Show more

Revenue $0
EBITDA -$23M -39.8%
Net Income -$22M -40.1%
EPS (Diluted) -0.76 +14.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -146.76% -39.7%
ROIC -
Debt/Equity 0.08
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 63.1% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 10.1x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-7.64%

EPS CAGR

10Y-

5Y-

3Y-

TTM10.34%

ROCE

10Y Avg-82.36%

5Y Avg-82.36%

3Y Avg-103.01%

Latest-148.86%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	842.5K	453.85K	1.35M	8.22M	16.14M	22.67M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	259.34K	205.7K	1.23M	4.02M	7.41M	11.38M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	583.16K	248.15K	126.53K	4.2M	8.74M	11.29M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-842.5K	-453.85K	-1.35M	-8.22M	-16.14M	-22.67M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	0.46%	-1.98%	-5.08%	-0.96%	-0.4%
EBITDA+	-841.42K	-451.53K	-1.35M	-8.22M	-16.14M	-22.56M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	0.46%	-1.99%	-5.09%	-0.96%	-0.4%
D&A (Non-Cash Add-back)	1.08K	2.32K	2.47K	2.13K	5.47K	115.39K
EBIT	-842.5K	-453.85K	-24.2M	-8.22M	-16.14M	-22.67M
Net Interest Income+	-109.98K	-101.98K	-179.85K	-497	572.01K	1.02M
Interest Income	0	0	0	0	572.01K	1.02M
Interest Expense	109.98K	101.98K	179.85K	497	0	0
Other Income/Expense	-109.76K	-676.46K	-23.03M	-497	572.01K	1.02M
Pretax Income+	-952.26K	-1.13M	-24.38M	-8.22M	-15.57M	-21.66M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	20.55K	17.55K	6.01K	10.27K	26.41K	41.04K
Effective Tax Rate %	1.02%	1.02%	1%	1%	0.99%	1%
Net Income+	-972.81K	-1.15M	-24.38M	-8.23M	-15.43M	-21.61M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.18%	-20.24%	0.66%	-0.87%	-0.4%
Net Income (Continuing)	-972.81K	-1.15M	-24.38M	-8.23M	-15.6M	-21.7M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	-201.74K	0
EPS (Diluted)+	-0.29	-0.15	-6.64	-0.59	-0.89	-0.76
EPS Growth %	-	0.48%	-43.27%	0.91%	-0.51%	0.15%
EPS (Basic)	-0.29	-0.15	-6.64	-0.59	-0.89	-0.76
Diluted Shares Outstanding	3.38M	7.77M	3.67M	13.89M	17.34M	28.29M
Basic Shares Outstanding	3.38M	7.77M	3.67M	13.89M	17.34M	28.29M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	933.26K	532.24K	18.19M	14.9M	19.79M	20.2M
Cash & Short-Term Investments	734.01K	391.09K	17.64M	13.44M	17.51M	17.68M
Cash Only	734.01K	391.09K	17.64M	13.44M	17.51M	17.68M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	175.75K	127.44K	25.72K	255.71K	1.17M	1.97M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	78.07K	44.58K	32.27K
Total Non-Current Assets+	9.68K	7.36K	5.7K	10.28K	137.41K	2.75M
Property, Plant & Equipment	9.68K	7.36K	5.7K	3.56K	50.18K	2.73M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	6.72K	87.23K	20.42K
Total Assets+	942.94K	539.6K	18.19M	14.91M	19.93M	22.95M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.43%	32.71%	-0.18%	0.34%	0.15%
Total Current Liabilities+	4.59M	5.27M	202.04K	1.27M	3.72M	8.69M
Accounts Payable	247.54K	252.34K	142.94K	143.07K	1.43M	5.39M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	4.1M	4.1M	50K	0	0	0
Deferred Revenue (Current)	0	342.84K	0	0	0	0
Other Current Liabilities	0	232.16K	0	0	0	658.16K
Current Ratio	0.20x	0.10x	90.01x	11.70x	5.32x	2.33x
Quick Ratio	0.20x	0.10x	90.01x	11.70x	5.32x	2.33x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	475K	0	1.01M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	1.01M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	475K	0	0
Total Liabilities	4.59M	5.27M	202.04K	1.75M	3.72M	9.7M
Total Debt+	4.1M	4.1M	50K	0	0	1.07M
Net Debt	3.37M	3.71M	-17.59M	-13.44M	-17.51M	-16.61M
Debt / Equity	-	-	0.00x	-	-	0.08x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-7.66x	-4.45x	-7.52x	-16537.12x	-	-
Total Equity+	-3.65M	-4.73M	17.99M	13.16M	16.2M	13.25M
Equity Growth %	-	-0.3%	4.8%	-0.27%	0.23%	-0.18%
Book Value per Share	-1.08	-0.61	4.90	0.95	0.93	0.47
Total Shareholders' Equity	-3.65M	-4.73M	17.99M	13.16M	16.41M	13.25M
Common Stock	338	338	1.32K	1.4K	2K	2.76K
Retained Earnings	-4.22M	-5.37M	-29.76M	-37.99M	-53.41M	-75.02M
Treasury Stock	0	0	0	-99.96K	-99.96K	-99.96K
Accumulated OCI	68.22K	131.86K	125.41K	87.02K	134.67K	-1.06K
Minority Interest	0	0	0	0	-201.74K	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-790.03K	-404.69K	-1.59M	-7.41M	-11.37M	-14.6M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	0.49%	-2.93%	-3.66%	-0.53%	-0.28%
Net Income	-972.81K	-1.15M	-24.38M	-8.23M	-15.6M	-21.61M
Depreciation & Amortization	1.08K	2.32K	2.47K	2.13K	5.47K	115.39K
Stock-Based Compensation	0	0	218.98K	624.07K	2.57M	0
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	0	575K	22.96M	0	0	2.94M
Working Capital Changes	181.7K	165.85K	-391.04K	195.21K	1.65M	3.97M
Change in Receivables	-36.29K	58.49K	97.67K	-236.38K	-893.4K	-971.53K
Change in Inventory	36.29K	0	0	0	0	0
Change in Payables	122.95K	-3.83K	-106.06K	1.13M	2.43M	4.4M
Cash from Investing+	-7.31K	0	-802	0	-52.09K	-1.18M
Capital Expenditures	-7.31K	0	-802	0	-52.09K	-1.18M
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	1.05M	0	18.85M	3.23M	15.46M	15.95M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	0	-6.72K	-232K	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-797.34K	-404.69K	-1.59M	-7.41M	-11.42M	-15.77M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	0.49%	-2.93%	-3.66%	-0.54%	-0.38%
FCF per Share	-0.24	-0.05	-0.43	-0.53	-0.66	-0.56
FCF Conversion (FCF/Net Income)	0.81x	0.35x	0.07x	0.90x	0.74x	0.68x
Interest Paid	67	899	1.54K	9.6K	0	0
Taxes Paid	20.55K	17.55K	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-367.8%	-52.84%	-105.07%	-146.76%
Return on Invested Capital (ROIC)	-	-	-256.34%	-10389.53%	-	-
Debt / Equity	-	-	0.00x	-	-	0.08x
Interest Coverage	-7.66x	-4.45x	-7.52x	-16537.12x	-	-
FCF Conversion	0.81x	0.35x	0.07x	0.90x	0.74x	0.68x

Frequently Asked Questions

Growth & Financials

Immix Biopharma, Inc. (IMMX) grew revenue by 0.0% over the past year. Growth has been modest.

Immix Biopharma, Inc. (IMMX) reported a net loss of $23.6M for fiscal year 2024.

Dividend & Returns

Immix Biopharma, Inc. (IMMX) has a return on equity (ROE) of -146.8%. Negative ROE indicates the company is unprofitable.

Immix Biopharma, Inc. (IMMX) had negative free cash flow of $15.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener